Cardio Lab · DeCure for X
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for hypertrophic cardiomyopathy 25 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for hypertrophic cardiomyopathy 25 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
titin-cap (TCAP) — TCAP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 2F8V · 2.75 Å · ligand none (apo structure). Experimental structure, not a prediction.
Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder caused by mutations in sarcomeric proteins, with a highly variable clinical presentation. Some individuals remain asymptomatic while others have significant limitation of functional status. The condition is characterised by left ventricular hypertrophy not explained by another cause, and patients are further classified based on whether there is obstruction of the left ventricular outflow tract. A 2023 scoping review notes that causes include genetic mutations and mitochondrial dysfunction, but the precise relationship between these factors remains unclear.
As of 2021, there are no pharmacologic therapies that alter the natural history of the disease. Therapeutic approaches have instead focused on symptom relief and prevention of sudden cardiac death. Newer therapies under investigation represent potential means to improve limiting symptoms, but no concrete survival or response rate data from clinical trials are provided in these abstracts.
The 2023 review states that understanding the early mechanisms of HCM is crucial for the development of effective therapies, but it does not report any tested drug, sample size, or outcome numbers. The 2013 overview is a general clinical summary for nurse practitioners and contains no original data.
What is still missing are completed clinical trials with survival or response rate endpoints, funding for mechanism-based drug development, and patient stratification strategies to account for the variable clinical presentation and genetic heterogeneity of the disease.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractThis article presents an overview of hypertrophic cardiomyopathy (HCM) and the associated clinical findings, treatment, and management for nurse practitioners. Topics include an overview of the condition, major and minor criteria for diagnosis, clinical course and pathophysiology, genetic inheritance and testing, and dysrhythmias associated with HCM.
https://doi.org/10.1097/01.npr.0000428814.64880.f2AbstractHypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining asymptomatic and others having significant limitation of functional status. The disorder is typically characterized by left ventricular hypertrophy that is not explained by another cause. Patients are further classified based on whether there is obstruction of the left ventricular outflow tract. To-date, there are no pharmacologic therapies that alter the natural history of the disease. Therapeutic approaches have instead focused on symptom relief and prevention of sudden cardiac death. Newer therapies under investigation represent potential means to improve limiting symptoms.
https://doi.org/10.37765/ajmc.2021.88628AbstractHypertrophic cardiomyopathy (HCM) is a cardiac condition characterized by left ventricular hypertrophy and diastolic dysfunction, posing a risk of sudden cardiac death. The causes of HCM are diverse, including genetic mutations and mitochondrial dysfunction, but the precise relationship between these factors remains unclear. This project focuses on investigating this association, as understanding the early mechanisms of HCM is crucial for the development of effective therapies, aiming to contribute to future advances in the treatment of this cardiac condition.
https://doi.org/10.17605/osf.io/xjgvcDisease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
